• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

8.700 +0.090 (+1.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 45,430,249
Open 8.630
Bid (Size) 8.690 (100)
Ask (Size) 8.700 (3,700)
Prev. Close 8.610
Today's Range 8.320 - 9.250
52wk Range 1.830 - 9.250
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ↗
February 20, 2026
ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time. 
Via Stocktwits
News headline image
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
February 20, 2026
From ImmunityBio, Inc.
Via Business Wire

Performance

YTD
+330.7%
+330.7%
1 Month
+18.5%
+18.5%
3 Month
+304.7%
+304.7%
6 Month
+286.7%
+286.7%
1 Year
+154.4%
+154.4%

More News

Read More
News headline image
Nasdaq, S&P 500 Futures Rise Before PCE Report, Likely Tariff Ruling: Why NVDA, TSLA, GOOGL, IBRX, APP, GRAL Are On Traders' Radar Today ↗
February 20, 2026
Via Stocktwits
Topics ETFs Economy Government
News headline image
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug ↗
February 20, 2026
Via Stocktwits
Topics Government
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
February 19, 2026
Via Finterra
Topics Lawsuit
News headline image
ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries ↗
February 19, 2026
Via Stocktwits
News headline image
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
February 19, 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
February 19, 2026
Via Stocktwits
Topics ETFs Economy Government
News headline image
Why IBRX Stock Became A High-Stakes Showdown Between Shorts And Retail Bulls ↗
February 18, 2026
Via Stocktwits
News headline image
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer ↗
February 18, 2026
Via The Motley Fool
Topics Initial Public Offering Stocks
Here are the top movers in Wednesday's session. ↗
February 18, 2026
Via Chartmill
News headline image
Why ImmunityBio Stock Is Soaring Today ↗
February 18, 2026
Via The Motley Fool
Discover the most active stocks in Wednesday's session. ↗
February 18, 2026
Via Chartmill
Top movers in Wednesday's session ↗
February 18, 2026
Via Chartmill
News headline image
IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally ↗
February 18, 2026
Via Stocktwits
News headline image
ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries
February 18, 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
How High Can IBRX Stock Go Now? Here’s What Wall Street Thinks After Saudi Nod For Bladder Cancer Filing ↗
February 18, 2026
Via Stocktwits
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
February 17, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’ ↗
February 17, 2026
Via Stocktwits
News headline image
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia
February 17, 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗
February 17, 2026
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals ↗
February 17, 2026
Via Stocktwits
News headline image
IBRX Stokes Retail Chatter — Investors See Anktiva Beat Merck’s Keytruda With Approval In EU ↗
February 13, 2026
Via Stocktwits
News headline image
ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC)
February 10, 2026
Via AB Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
February 03, 2026
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 8.700
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 02/20/26 04:00 PM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 3.40B
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap